NFκB p65 Antibody (F-6) is an IgG₁ κ mouse monoclonal NF kappa B p65 antibody (also designated RelA antibody, p65 antibody or NFKB3 antibody) that detects the NF kappa B p65 protein of mouse, rat and human origin by WB, IP, IF, IHC(P), FCM and ELISA. NFκB p65 Antibody (F-6) is available as both the non-conjugated anti-NF kappa B p65 antibody form, as well as multiple conjugated forms of anti-NF kappa B p65 antibody, including agarose, HRP, PE, FITC and multiple Alexa Fluor^® conjugates. Proteins encoded by the v-Rel viral oncogene and its cellular homolog, c-Rel, are members of a family of transcription factors that include the two subunits of the transcription factor NκB (p50 and p65) and the Drosophila maternal morphogen, dorsal. Both proteins specifically bind to DNA sequences that are the same or slight variations of the 10 bp κB sequence in the immunoglobulin κ light chain enhancer. This same sequence is also present in a number of other cellular and viral enhancers. The DNA binding activity of NFκB is activated and NFκB is subsequently transported from the cytoplasm to the nucleus in cells exposed to mitogens or growth factors. cDNAs encoding precursors for two distinct proteins of the same size have been described, designated p105 and p100. The p105 precursor contains p50 at its N-terminus and a C-terminal region that when expressed as a separate molecule, designated pdI, binds to p50 and regulates its activity.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

References:

1. The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding.  |  Hatada, EN., et al. 1992. Proc Natl Acad Sci U S A. 89: 2489-93. PMID: 1532257
2. Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation.  |  Perkins, ND., et al. 1992. Proc Natl Acad Sci U S A. 89: 1529-33. PMID: 1542644
3. The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression.  |  Ballard, DW., et al. 1992. Proc Natl Acad Sci U S A. 89: 1875-9. PMID: 1542686
4. Cloning, expression and characterization of the bovine p65 subunit of NFkappaB.  |  Doleschall, M., et al. 2007. Dev Comp Immunol. 31: 945-61. PMID: 17306370
5. Hypertension aggravates glomerular dysfunction with oxidative stress in a rat model of diabetic nephropathy.  |  Tomohiro, T., et al. 2007. Life Sci. 80: 1364-72. PMID: 17331548
6. Glucocorticoid receptor, nuclear factor kappaB, activator protein-1 and C-jun N-terminal kinase in systemic lupus erythematosus patients.  |  Oikonomidou, O., et al. 2006. Neuroimmunomodulation. 13: 194-204. PMID: 17347585
7. Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.  |  Matthews, CP., et al. 2007. Cancer Res. 67: 2430-8. PMID: 17363560
8. Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65.  |  Schmid, RM., et al. 1991. Nature. 352: 733-6. PMID: 1876189
9. Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha.  |  Meyer, R., et al. 1991. Proc Natl Acad Sci U S A. 88: 966-70. PMID: 1992489

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-RELA/NFκB p65 Antibody (F-6) has 2,206 citations in a variety of scientific publications.

Primary antibodies like Anti-RELA/NFκB p65 Antibody (F-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.